1998
DOI: 10.1300/j094v06n02_12
|View full text |Cite
|
Sign up to set email alerts
|

A Novel Treatment for Fibromyalgia Improves Clinical Outcomes in a Community-Based Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
2
0
3

Year Published

2006
2006
2022
2022

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 19 publications
(5 citation statements)
references
References 22 publications
0
2
0
3
Order By: Relevance
“…Analysiert wurden 9 RCT mit 420 Patienten und einer durchschnittlichen Behandlungsdauer von 11 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) Wochen. In 7 Studien wurden nach durchschnittlich 20 (6-78) Wochen Nachuntersuchungen durchgeführt (Evidenzbericht, .…”
Section: Starke Empfehlungenunclassified
See 2 more Smart Citations
“…Analysiert wurden 9 RCT mit 420 Patienten und einer durchschnittlichen Behandlungsdauer von 11 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) Wochen. In 7 Studien wurden nach durchschnittlich 20 (6-78) Wochen Nachuntersuchungen durchgeführt (Evidenzbericht, .…”
Section: Starke Empfehlungenunclassified
“…Die mittlere Nachuntersuchungszeit von 3 Studien lag bei 17 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28) Wochen (Evidenzbericht, . Tab.…”
Section: Starke Empfehlungenunclassified
See 1 more Smart Citation
“…Therefore, we investigated the role of the − 169C/T variant (rs7528684) in a Finnish Type 1 diabetes case-control sample from the FinnDiane study [4]. A total of 735 cases and 735 non-diabetic healthy controls were genotyped using fluorogenic 5 ′ nuclease allelic discrimination chemistry (TaqMan®) with an ABI Prism® 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA).…”
Section: The Functional Variant − − − − 169c/t In the Fcrl3 Gene Doesmentioning
confidence: 99%
“…Recently, in a community‐based randomized clinical trial, we identified such reactivities in cohorts of patients with Type 1 ( n = 27) and Type 2 ( n = 26) diabetes. Patients undertook conventional ‘best practices’ diabetes management alone (control arm, 13 in each cohort) or additionally carried out a novel patient‐specific comprehensive care protocol (test arm, 14 Type 1 and 13 Type 2 diabetics): test patients substituted for their reactive antigens and were advised to follow a repair‐stimulating diet including nutrient supplementation plans as detailed previously [4]. Biweekly support group meetings were held where qualified nutritionists provided on‐going guidance and instruction to implement their plan.…”
mentioning
confidence: 99%